Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Jan;41(1):24-9.
doi: 10.1124/dmd.112.048546. Epub 2012 Sep 20.

Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase

Affiliations

Evidence for substrate-dependent inhibition profiles for human liver aldehyde oxidase

John T Barr et al. Drug Metab Dispos. 2013 Jan.

Abstract

The goal of this study was to provide a reasonable assessment of how probe substrate selection may impact the results of in vitro aldehyde oxidase (AO) inhibition experiments. Here, we used a previously studied set of seven known AO inhibitors to probe the inhibition profile of a pharmacologically relevant substrate N-[(2-dimethylamino)ethyl]acridine-4-carboxamide (DACA). DACA oxidation in human liver cytosol was characterized with a measured V(max) of 2.3 ± 0.08 nmol product · min(-1) · mg(-1) and a K(m) of 6.3 ± 0.8 µM. The K(ii) and K(is) values describing the inhibition of DACA oxidation by the panel of seven inhibitors were tabulated and compared with previous findings with phthalazine as the substrate. In every case, the inhibition profile shifted to a much less uncompetitive mode of inhibition for DACA relative to phthalazine. With the exception of one inhibitor, raloxifene, this change in inhibition profile seems to be a result of a decrease in the uncompetitive mode of inhibition (an affected K(ii) value), whereas the competitive mode (K(is)) seems to be relatively consistent between substrates. Raloxifene was found to inhibit competitively when using DACA as a probe, and a previous report showed that raloxifene inhibited uncompetitively with other substrates. The relevance of these data to the mechanistic understanding of aldehyde oxidase inhibition and potential implications on drug-drug interactions is discussed. Overall, it appears that the choice in substrate may be critical when conducting mechanistic inhibition or in vitro drug-drug interactions prediction studies with AO.

PubMed Disclaimer

Figures

Scheme 1.
Scheme 1.
DACA oxidation reaction catalyzed by AO in HLC.
Fig. 1.
Fig. 1.
Michaelis-Menten curve fit and solved kinetic parameters for the oxidation of DACA in HLC. Each point represents a mean of at least seven determinations. Solved parameters are from the best global fit ± S.E.M.
Fig. 2.
Fig. 2.
Structures of AO inhibitors used in Ki studies.
Fig. 3.
Fig. 3.
L-B plots comparing the inhibition of the AO-catalyzed oxidation of two different substrates in HLC: phthalazine (left) and DACA (right). Inset graphs are subsequent replots of slope and/or y-intercept of the L-B plots. The top two panels show inhibition by estradiol, center panels show inhibition by clozapine, and bottom panels show inhibition by chlorpromazine. Each point represents the mean ± S.E.M. of a single assay vial analyzed in triplicate by LC-MS/MS.
Fig. 4.
Fig. 4.
L-B plot of the inhibition of AO-catalyzed DACA oxidation by raloxifene. Inset graph is a subsequent replot of L-B slopes versus inhibitor concentration. Each point represents the mean ± S.E.M. of a single assay vial analyzed in triplicate by LC-MS/MS.

References

    1. Atwell GJ, Rewcastle GW, Baguley BC, Denny WA. (1987) Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide. J Med Chem 30:664–669 - PubMed
    1. Barr JT, Jones JP. (2011) Inhibition of human liver aldehyde oxidase: implications for potential drug-drug interactions. Drug Metab Dispos 39:2381–2386 - PMC - PubMed
    1. Cook PB, Cleland WW. (2007) Enzyme Kinetics and Mechanism, Garland Science, New York
    1. Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. (2010) Selection of alternative CYP3A4 probe substrates for clinical drug interaction studies using in vitro data and in vivo simulation. Drug Metab Dispos 38:981–987 - PubMed
    1. Foti RS, Wahlstrom JL. (2008) CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos 36:523–528 - PubMed

Publication types

Substances